Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

WPD Pharmaceuticals Inc. (C:WBIO)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for WBIO within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 11, 2021 07:30 ET
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National...
Read full article
May 05, 2021 12:26 ET
WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements
WPD Pharmaceuticals Inc. (the “Company”) (CSE: WBIO) (FSE: 8SV1), announces that further to its news release dated April 29, 2021 it has received approval from the British Columbia Securities Commission for a temporary management cease trade order...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
24.65
14.28
Price to Book - most recent quarter
11.59
6.30
3.96
Price to Cash Flow per share - TTM
--
15.15
17.61
Price to Free Cash Flow per share - TTM
--
--
31.57
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Apr 30, 202132,562-20,061
Apr 15, 202152,6232,890
Mar 31, 202149,73329,718
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

WPD Pharmaceuticals Inc, formerly Westcot Ventures Corp, is a Canada-based biotechnology research and development company. The Company focuses on oncology, research and development of medicinal products involving biological compounds and small molecules. The Company has approximately 10 drug candidates with five that are in clinical development stage and five in pre-clinical development. The Company's drug development focuses on melanoma, brain cancer, leukemia and pancreatic cancer. Its portfolio for brain cancer includes WPD101, Berubicin and WP1066. Its portfolio for pancreatic cancer includes WP1066 and WP1732. Its portfolio for other cancers include WPD103, WP1220 and Annamycin.

See business summary

 

Twitter

Search (past week) for $WBIO.CA

  • No tweets found